An international study published on Sept. 23, 2026, in The New England Journal of Medicine reveals that performing hematopoietic cell transplantation (HCT) before malignant transformation occurs can improve survival rates for patients with Shwachman-Diamond syndrome (SDS). Co-led by Kasiani Myers of Cincinnati Children’s and backed by the International SDS Research Consortium, the research tracked 847 cases across the lifespan, demonstrating that cumulative risks of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and bone marrow failure approach 78% by age 50, making timely pre-emptive intervention critical.
Shwachman-Diamond Syndrome Survival Rates Drop After Age Twenty
While more than 90% of children born with SDS survive past the age of 20, long-term survival declines substantially afterward, according to the international cohort data. The rare genetic disorder, typically caused by a mutated SBDS gene inherited from both parents, affects multiple bodily systems. According to the Shwachman-Diamond Syndrome Foundation, about 400 patients live with the condition in the United States, though advocates estimate undiagnosed or misdiagnosed cases could push that number as high as 3,000. Described initially in 1964 by doctors Harry Shwachman and Louis Diamond, SDS presents early in life through physical exams and blood tests checking for symptoms like failure to thrive, digestive enzyme shortages, and low white blood cell counts.
Early Hematopoietic Cell Transplantation Boosts Two-Year Survival
The research team examined outcomes for 24 high-risk patients who underwent HCT after developing abnormal mutated bone marrow clones or progressive dysplasia, but before a formal diagnosis of MDS or AML. Approximately 82% of these patients were alive two years post-transplantation. In contrast, two-year survival was approximately 55% for patients who received transplants after developing MDS, and 36% for those transplanted after the onset of AML. These findings indicate that waiting for overt malignancy may be associated with poorer outcomes.
Clinical Insight: While 5-year-olds face a lethal malignancy incidence as low as 2%, the progressive cumulative risk of bone marrow failure and leukemia climbs steeply over decades, prompting researchers to advocate for risk-adapted HCT strategies.
%2c_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg "Photo: news-medical.net")
Surveillance and Genetic Testing Challenges in Modern Care
To catch high-risk biomarkers before cancer develops, researchers recommend rigorous clinical and molecular surveillance throughout a patient’s lifespan. Expanding access to genetic screening can help diagnose infants before severe complications arise. However, stem cell transplants carry substantial medical risks and significant costs, which can restrict access for young patients in low-resource settings. Myers and fellow consortium members note that further investigations are necessary to pinpoint exact risk factors and optimal ages for pre-emptive HCT without exposing non-indicated patients to unnecessary procedure-related dangers.
Frequently Asked Questions About Shwachman-Diamond Syndrome
What causes Shwachman-Diamond syndrome?
SDS is a rare genetic disorder requiring both parents to pass down a mutated gene, most commonly the SBDS gene.
What are the primary long-term risks of SDS?
The most serious outcomes of the condition are the development of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and bone marrow failure, which affect nearly 78% of patients by age 50 according to the 2026 New England Journal of Medicine study.
Why is early HCT recommended by researchers?
Data from the International SDS Research Consortium show that patients undergoing transplantation after detecting high-risk features—but before malignant transformation—have an 82% two-year survival rate, compared to significantly lower survival rates for those treated after MDS or AML diagnosis.
Are standard newborn screenings able to detect SDS?
No, standard prenatal and newborn screening tests do not screen for SDS. The condition is usually identified during infancy through targeted physical examinations and blood tests.
Related reading